Ozzy is a specialized tracker for GLP-1 medication users on iOS, focused on injection logging, symptom tracking, and clinical report generation.
The App DNA
What makes this app unique?
Users need a reliable way to track medication side effects and injection history to facilitate informed discussions with their healthcare providers during long-term treatment.
For Individuals prescribed GLP-1 medications who require a focused tool for tracking medication adherence and side effects.
What does it look like?
Key features
Records medication doses, pen clicks, and injection site rotation to drive daily habit formation.
Generates a summary report of injection history and symptoms for physician review, increasing long-term utility.
Syncs weight, steps, and sleep data to reduce manual entry friction.
How much does it cost?
Ozzy is currently free with no visible subscription or IAP gates, focusing on user acquisition and category authority.
Velocity
Maintenance developmentUX improvementsShow more...
The app maintains a maintenance-tier cadence, shipping only one release in the last 61 days. Development is currently focused on UX improvements and streamlining the logging process for GLP-1 medications. There is no evidence of a live-ops strategy or high-frequency feature deployment. The current pace suggests a focus on stability and core functionality rather than rapid iteration.
Who built it?
Igor Krupski
2 apps tracked · Health & Fitness
GutLog: Poop Tracker, IBS LogUser Sentiment
What do users think recently?
How are ratings & reviews evolving?
Not enough recent reviews to extract reliable themes yet.
Read the full review analysisCompetition
Competitive landscape for Ozzy - Ozempic & GLP1 Tracker
How's the Health & Fitness market?
Ozzy maintains a 5.0-star rating across 23 reviews, positioning itself as a high-utility, niche tool within the Health & Fitness category. The lack of recent updates (62 days since last release) suggests a stable, mature product rather than a high-velocity growth play.
Read the market outlookThe rivals identified
Unlock the deeper market read.
Access the full report for freeThe Analyst's Read
Key takeaways for Ozzy - Ozempic & GLP1 Tracker
Where is it heading?
Users report: The market for GLP-1 tracking is shifting toward specialized, high-utility tools that integrate with clinical workflows. Ozzy is well-positioned to capture this segment by focusing on physician-ready data, but it must avoid stagnation by adding proactive features like refill management to defend its user base against broader health platforms.
- The 5.0-star rating indicates the current feature set perfectly serves the core user need for medication tracking.
- The 62-day update gap suggests a stable product, but requires a roadmap for new features to prevent long-term churn.
The SWOT
- Clinical PDF export functionality creates a high-value, low-friction bridge to physician consultations.
- Focused, ad-free interface removes the cognitive load associated with broader, AI-stuffed health apps.
- Automated pharmacy refill reminders could deepen the retention loop for chronic medication users.
- Expansion into community-based symptom sharing could provide peer-support value without compromising the app's calm design.
Next best moves
Ship automated refill reminders because users report medication consistency is a primary goal → increase long-term retention
+ 1 more prioritized moveThe counter-intuitive read
Ozzy's maintenance-mode status is a feature, not a bug…
Read the full takeSince the last report: The product remains in a stable maintenance state, with no changes to features or pricing. The primary shift is a transition in the strategic outlook, moving from a focus on monetization to a roadmap centered on retention-driving features like refill reminders.
Bottom line
Ozzy's clinical PDF export provides a clear, defensible utility that keeps users engaged throughout their treatment journey. Prioritizing medication-specific features like refill reminders will solidify this position, ensuring the app remains essential even as broader health platforms enter the space.
Unlock 2 critical frictions, 2 market threats, 1 more prioritized move and the analyst’s take.
Access the full report for freeSources
- [1] App Store, source
Report last updated